GlassScriptPhysician profile
Christine M Toth
NPI 1851367668
$3,459.24
in general payments reported to CMS, 2019-2025
28 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $269 · 2021: $417 · 2022: $695 · 2023: $382 · 2024: $571 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425 · Education: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.57 |
| Education | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $822.27 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $349.69 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $280.86 | 2021-2025 | |
| Amgen INC. | $247.82 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Veloxis Pharmaceuticals, INC. | $181.53 | 2019-2025 | Envarsus |
| Mallinckrodt Hospital Products INC. | $170.94 | 2020-2023 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $141.58 | 2020-2024 | Veltassa |
| Janssen Pharmaceuticals, INC | $138.79 | 2019-2022 | |
| Horizon Therapeutics Plc | $138.19 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $125.73 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $103.81 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $102.26 | 2021-2024 | Lupkynis |
| Travere Therapeutics, INC. | $101.17 | 2019-2025 | |
| Akebia Therapeutics INC | $99.26 | 2019 | |
| Daiichi Sankyo INC. | $89.62 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $66.08 | 2022-2023 | Jesduvroq, Benlysta |
| Calliditas Therapeutics US INC. | $56.72 | 2023-2025 | Tarpeyo |
| Novo Nordisk INC | $50.43 | 2023-2025 | Wegovy, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $37.09 | 2021-2022 | |
| Ardelyx, INC. | $31.63 | 2025 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $17.59 | 2025 | |
| Fresenius USA Marketing, INC. | $17.45 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.09 | 2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $16.66 | 2019 | |
| Hikma Pharmaceuticals USA | $14.77 | 2020 | |
| Alnylam Pharmaceuticals INC. | $14.71 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.52 | 2023 | Keveyis |
| Mallinckrodt Enterprises LLC | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Toth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.